MX2019006523A - Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. - Google Patents

Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.

Info

Publication number
MX2019006523A
MX2019006523A MX2019006523A MX2019006523A MX2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A
Authority
MX
Mexico
Prior art keywords
preservation
immune response
response during
chemotherapy regimens
during chemotherapy
Prior art date
Application number
MX2019006523A
Other languages
English (en)
Inventor
C Strum Jay
A Sorrentino Jessica
Y Lai Anne
Joseph Roberts Patrick
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of MX2019006523A publication Critical patent/MX2019006523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La adición de un inhibidor CDK 4/6 de semivida corta, de acción rápida, selectivo en un régimen de dosificación muy específico a la combinación de quimioterapia con un inhibidor de punto de control proporciona resultados superiores en el tratamiento de un tumor o cáncer. El descubrimiento inesperado es que la administración específicamente cronometrada pulsátil corta de un inhibidor CDK 4/6 de semivida corta, de acción rápida, selectivo durante la administración de la porción de quimioterapia de la terapia de combinación triple tiene un efecto profundo en las células inmunitarias en el microambiente del cáncer.
MX2019006523A 2016-12-05 2017-12-05 Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. MX2019006523A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430302P 2016-12-05 2016-12-05
US201762479605P 2017-03-31 2017-03-31
PCT/US2017/064775 WO2018106729A1 (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens

Publications (1)

Publication Number Publication Date
MX2019006523A true MX2019006523A (es) 2019-10-15

Family

ID=62491342

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019006523A MX2019006523A (es) 2016-12-05 2017-12-05 Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.
MX2023006991A MX2023006991A (es) 2016-12-05 2019-06-04 Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006991A MX2023006991A (es) 2016-12-05 2019-06-04 Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.

Country Status (12)

Country Link
US (2) US11529352B2 (es)
EP (1) EP3548030A4 (es)
JP (3) JP2019536805A (es)
KR (4) KR20240023676A (es)
CN (3) CN117562905A (es)
AU (3) AU2017372856B9 (es)
BR (1) BR112019011410A2 (es)
CA (1) CA3045465A1 (es)
IL (3) IL311265A (es)
MX (2) MX2019006523A (es)
NZ (1) NZ753631A (es)
WO (1) WO2018106729A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2968290T (pt) 2013-03-15 2019-11-27 G1 Therapeutics Inc Protecção transitória de células normais durante a quimioterapia
ES2836772T3 (es) 2014-04-30 2021-06-28 Fujifilm Corp Composición liposomal y método para producirla
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20240023676A (ko) 2016-12-05 2024-02-22 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
AU2018246024B2 (en) 2017-03-31 2020-08-06 Fujifilm Corporation Liposome composition and pharmaceutical composition
WO2019054865A1 (en) * 2017-09-14 2019-03-21 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) IMMUNOTHERAPY BASED ON T-LYMPHOCYTES
WO2019108589A1 (en) * 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
CA3087570A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
TW202402301A (zh) * 2018-06-20 2024-01-16 日商富士軟片股份有限公司 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥
CN112312895B (zh) * 2018-06-20 2023-05-09 富士胶片株式会社 包含内含药物的脂质体组合物及免疫检查点抑制剂的组合医药
CN113396160A (zh) * 2018-09-19 2021-09-14 国家医疗保健研究所 治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
WO2020219926A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer with cdk inhibitors
CA3133821A1 (en) * 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
CA3143339A1 (en) * 2019-06-18 2020-12-24 G1 Therapeutics, Inc. Patient selection for enhancement of anti-tumor immunity in cancer patients
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
IL298294A (en) 2020-05-19 2023-01-01 G1 Therapeutics Inc Cyclin-dependent kinase inhibitory compounds for the treatment of medical disorders
WO2021257587A1 (en) * 2020-06-15 2021-12-23 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022087018A1 (en) * 2020-10-19 2022-04-28 G1 Therapeutics, Inc. Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
JP2023552440A (ja) * 2020-12-07 2023-12-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー アトラクチレノリドｉを用いて癌細胞を免疫攻撃に対して感受性にする方法
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
WO2023068220A1 (ja) * 2021-10-18 2023-04-27 株式会社Preferred Networks 予測方法及びバイオマーカー
WO2023164649A2 (en) * 2022-02-25 2023-08-31 Lanier Biotherapeutics, Inc. Anti-alarmin binding molecules and treatment of pneumonitis
WO2024050145A1 (en) * 2022-09-02 2024-03-07 Rs Oncology, Llc Thiostrepton dosing regimens

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
US20090098137A1 (en) 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101568529A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
WO2010012777A1 (en) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
EP2716643A1 (en) 2008-08-22 2014-04-09 Novartis AG Pyrrolopyrimidine compounds and their uses
CN102231984A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
WO2010051127A2 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
US20120100100A1 (en) 2009-05-13 2012-04-26 Sharpless Norman E Cyclin dependent kinase inhibitors and methods of use
RS55135B1 (sr) 2010-10-25 2016-12-30 G1 Therapeutics Inc Cdk inhibitori
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
MX359406B (es) 2011-07-01 2018-09-27 Novartis Ag Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer.
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
US10202392B2 (en) 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
PT2968290T (pt) 2013-03-15 2019-11-27 G1 Therapeutics Inc Protecção transitória de células normais durante a quimioterapia
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
KR20150141971A (ko) 2013-04-08 2015-12-21 파마싸이클릭스 엘엘씨 이브루티닙 병용 요법
CN105682683A (zh) * 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
AU2015314756A1 (en) 2014-09-13 2017-03-16 Novartis Ag Combination therapies of alk inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
EP3233123A4 (en) * 2014-12-16 2018-05-09 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
CN109661228A (zh) 2016-06-20 2019-04-19 库拉肿瘤学公司 用erk抑制剂治疗鳞状细胞癌
AU2017359333B2 (en) 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
JP7166252B2 (ja) 2016-11-30 2022-11-07 メディツィーニシェ・ウニヴェルジテート・インスブルック サイクリン依存性キナーゼ阻害剤としての３－アミノ－１，５－ジヒドロピラゾロ［３，４－ｄ］ピリミジン－４－オン
KR20240023676A (ko) 2016-12-05 2024-02-22 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
WO2018183479A1 (en) 2017-03-30 2018-10-04 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2019108589A1 (en) 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
JP2022116301A (ja) 2022-08-09
KR20190092478A (ko) 2019-08-07
EP3548030A1 (en) 2019-10-09
CN117562905A (zh) 2024-02-20
IL303038A (en) 2023-07-01
MX2023006991A (es) 2023-06-26
RU2019120160A (ru) 2021-01-11
US11529352B2 (en) 2022-12-20
BR112019011410A2 (pt) 2019-10-22
AU2017372856B9 (en) 2024-01-04
KR20240024296A (ko) 2024-02-23
AU2023282170A1 (en) 2024-01-04
KR20240023677A (ko) 2024-02-22
AU2017372856B2 (en) 2023-12-14
AU2023282168A1 (en) 2024-01-04
IL303038B1 (en) 2024-04-01
JP2019536805A (ja) 2019-12-19
CN117530948A (zh) 2024-02-09
CN110035759A (zh) 2019-07-19
CA3045465A1 (en) 2018-06-14
RU2019120160A3 (es) 2021-04-07
NZ753631A (en) 2023-07-28
IL266870A (en) 2019-08-29
WO2018106729A1 (en) 2018-06-14
US20190321370A1 (en) 2019-10-24
JP2023182577A (ja) 2023-12-26
JP7483791B2 (ja) 2024-05-15
US20230302001A1 (en) 2023-09-28
IL311265A (en) 2024-05-01
EP3548030A4 (en) 2020-08-12
AU2017372856A1 (en) 2019-06-06
KR20240023676A (ko) 2024-02-22

Similar Documents

Publication Publication Date Title
MX2023006991A (es) Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.
PH12016500841A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2017176628A8 (en) Methods for solid tumor treatment
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
MY188734A (en) Use of alphavirus in preparation of antitumor drugs
MX2017015896A (es) Agente anticancerigeno.
PH12020500555A1 (en) Esketamine for the treatment of depression
EA200801671A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
MY201804A (en) Administration and dosage of diaminophenothiazines
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
EA200900912A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
MX2017012991A (es) Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2017015532A (es) Terapia de combinacion pac-1.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2015009260A (es) Regimen de glicosidasa selectiva para programacion inmunitaria y tratamiento del cancer.
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
MX2021012931A (es) Polipeptidos multiespecificos activables y terapeuticos con semivida extendida.
PH12017500617A1 (en) Dosage regimen for pegylated interferon
EA201991313A1 (ru) Сохранение иммунного ответа во время химиотерапевтических схем